Amgen (NASDAQ:AMGN) had its target price upped by Wells Fargo & Co from $197.00 to $202.00 in a research note published on Monday morning, BenzingaRatingsTable reports. The brokerage currently has a market perform rating on the medical research company’s stock.

Other equities research analysts also recently issued reports about the company. BidaskClub upgraded Amgen from a sell rating to a hold rating in a research report on Thursday, August 1st. Citigroup upgraded Amgen from a neutral rating to a buy rating and decreased their target price for the stock from $211.00 to $205.00 in a research report on Wednesday, May 22nd. JPMorgan Chase & Co. reiterated a hold rating and issued a $190.00 target price on shares of Amgen in a research report on Wednesday, May 15th. Royal Bank of Canada reiterated a hold rating on shares of Amgen in a research report on Sunday, August 11th. Finally, Morgan Stanley decreased their target price on Amgen from $211.00 to $207.00 and set an overweight rating on the stock in a research report on Monday, July 15th. Nine analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $211.44.

NASDAQ AMGN opened at $199.31 on Monday. The company has a quick ratio of 2.60, a current ratio of 2.89 and a debt-to-equity ratio of 2.58. The firm has a market cap of $123.61 billion, a price-to-earnings ratio of 14.08, a price-to-earnings-growth ratio of 2.42 and a beta of 1.19. Amgen has a twelve month low of $166.30 and a twelve month high of $211.90. The business has a 50-day moving average price of $183.54 and a 200-day moving average price of $182.71.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, July 30th. The medical research company reported $3.97 EPS for the quarter, topping analysts’ consensus estimates of $3.58 by $0.39. The company had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The firm’s revenue for the quarter was down 3.1% on a year-over-year basis. During the same period in the previous year, the business earned $3.83 earnings per share. Research analysts expect that Amgen will post 14.25 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 6th. Shareholders of record on Thursday, August 15th will be given a dividend of $1.45 per share. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $5.80 dividend on an annualized basis and a yield of 2.91%. Amgen’s dividend payout ratio (DPR) is presently 40.28%.

In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $187.58, for a total transaction of $375,160.00. Following the sale, the director now directly owns 16,336 shares in the company, valued at $3,064,306.88. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total value of $77,792.00. Following the sale, the director now owns 16,336 shares in the company, valued at $2,990,141.44. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,425 shares of company stock worth $804,312. Company insiders own 0.25% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Bangor Savings Bank grew its stake in Amgen by 2.1% in the first quarter. Bangor Savings Bank now owns 2,682 shares of the medical research company’s stock worth $510,000 after purchasing an additional 55 shares in the last quarter. Carroll Financial Associates Inc. grew its stake in Amgen by 0.8% in the second quarter. Carroll Financial Associates Inc. now owns 7,436 shares of the medical research company’s stock worth $1,370,000 after purchasing an additional 58 shares in the last quarter. Lincoln Capital Corp grew its stake in Amgen by 0.3% in the second quarter. Lincoln Capital Corp now owns 21,483 shares of the medical research company’s stock worth $3,959,000 after purchasing an additional 58 shares in the last quarter. Slow Capital Inc. grew its stake in Amgen by 0.4% in the second quarter. Slow Capital Inc. now owns 13,799 shares of the medical research company’s stock worth $2,543,000 after purchasing an additional 58 shares in the last quarter. Finally, Nicholas Hoffman & Company LLC. grew its stake in Amgen by 5.0% in the second quarter. Nicholas Hoffman & Company LLC. now owns 1,207 shares of the medical research company’s stock worth $222,000 after purchasing an additional 58 shares in the last quarter. Institutional investors and hedge funds own 78.96% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Read More: What is a Swap?

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.